HOOKIPA Pharma Inc. (HOOK)

0,8600 +0,0352 (+4,27%) A partir del 02:29PM EDT. Mercado abierto.

HOOKIPA Pharma Inc.

350 Fifth Avenue
72nd Floor Suite 7240
New York, NY 10118
United States
431 890 6360
https://www.hookipapharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 151

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Joern Aldag	CEO & Director	848,34k	N/A	1959
Dr. Reinhard Kandera Ph.D.	CFO & Director	607,5k	N/A	1969
Prof. Rolf M. Zinkernagel M.D., Ph.D.	Co-Founder	N/A	N/A	1944
Mr. Andreas Bergthaler	Co-Founder	N/A	N/A	N/A
Mr. Lukas Flatz	Co-Founder	N/A	N/A	N/A
Dr. Roman Necina Ph.D.	Chief Operations Officer	N/A	N/A	1968
Dr. Klaus Orlinger Ph.D.	Chief Scientific Officer	N/A	N/A	1978
Mr. Matthew L. S. Beck	Executive Director of Investor Relations	N/A	N/A	N/A
Mr. Michael Szumera	Executive Director of Communications	N/A	N/A	N/A
Dr. Mark Winderlich Ph.D.	Chief Development Officer	N/A	N/A	1986

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Gobierno corporativo

El ISS Governance QualityScore de HOOKIPA Pharma Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.